Literature DB >> 10646540

The butyrylcholinesterase K-variant shows similar cellular protein turnover and quaternary interaction to the wild-type enzyme.

C V Altamirano1, C F Bartels, O Lockridge.   

Abstract

A recent study has linked the butyrylcholinesterase (BChE) K-variant and the apolipoprotein epsilon4 isoform to late-onset Alzheimer's disease. These findings have been controversial and have led us to examine the differences between wild-type and K-variant BChE in enzyme activity, protein stability, and quaternary structure. J-variant BChE (E497V/A539T) was also studied because it is associated with the K-variant mutation. The K-variant mutation (A539T) is located in the C-terminal tetramerization domain. Wild-type, K-variant, and J-variant BChE were expressed in Chinese hamster ovary cells and purified. The purified enzymes had similar binding affinity (Km) values and catalytic rates for butyrylthiocholine and benzoylcholine. In pulse-chase studies the K-variant, J-variant, and wildtype BChE were degraded rapidly within the cell, with a half-time of approximately 1.5 h. Less than 5% of the intracellular BChE was exported. The C-terminal peptide containing the K-variant mutation interacted with itself as strongly as did the wild-type peptide in the yeast two-hybrid system. Both K-variant and wild-type BChE assembled into tetramers in the presence of poly-L-proline or the proline-rich attachment domain of the collagen tail. The native K-variant BChE in serum showed the same proportion of tetramers as the native serum wild-type BChE. We conclude that the K-variant BChE is similar to wild-type BChE in enzyme activity, protein turnover, and tetramer formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646540     DOI: 10.1046/j.1471-4159.2000.740869.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  Radiolabeled cyclosaligenyl monophosphates of 5-iodo-2'-deoxyuridine, 5-iodo-3'-fluoro-2',3'-dideoxyuridine, and 3'-fluorothymidine for molecular radiotherapy of cancer: synthesis and biological evaluation.

Authors:  Zbigniew P Kortylewicz; Yu Kimura; Kotaro Inoue; Elizabeth Mack; Janina Baranowska-Kortylewicz
Journal:  J Med Chem       Date:  2012-03-08       Impact factor: 7.446

2.  Butyrylcholinesterase in SH-SY5Y human neuroblastoma cells.

Authors:  Seda Onder; Lawrence M Schopfer; Wei Jiang; Ozden Tacal; Oksana Lockridge
Journal:  Neurotoxicology       Date:  2022-02-18       Impact factor: 4.294

3.  Genetic Testing for BCHE Variants Identifies Patients at Risk of Prolonged Neuromuscular Blockade in Response to Succinylcholine.

Authors:  Guang-Dan Zhu; Eric Dawson; Angela Huskey; Ronald J Gordon; Andria L Del Tredici
Journal:  Pharmgenomics Pers Med       Date:  2020-09-30

4.  Amino-acid mutations to extend the biological half-life of a therapeutically valuable mutant of human butyrylcholinesterase.

Authors:  Lei Fang; Shurong Hou; Liu Xue; Fang Zheng; Chang-Guo Zhan
Journal:  Chem Biol Interact       Date:  2014-02-25       Impact factor: 5.192

5.  Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.

Authors:  Steven Ferris; Agneta Nordberg; Hilkka Soininen; Taher Darreh-Shori; Roger Lane
Journal:  Pharmacogenet Genomics       Date:  2009-08       Impact factor: 2.089

6.  Butyrylcholinesterase K variant and the APOE-epsilon 4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients.

Authors:  Asad Vaisi-Raygani; Zohreh Rahimi; Haidar Tavilani; Tayebeh Pourmotabbed
Journal:  Mol Biol Rep       Date:  2009-08-15       Impact factor: 2.316

7.  Gestational diabetes mellitus (GDM) decreases butyrylcholinesterase (BChE) activity and changes its relationship with lipids.

Authors:  Larissa O Guimarães; Fabiana A de Andrade; Gleyse F Bono; Thaís E Setoguchi; Mariana B Brandão; Eleidi A Chautard-Freire-Maia; Izabella C R Dos Santos; Geraldo Picheth; Ana Cristina R de A Faria; Rosângela R Réa; Ricardo L R Souza; Lupe Furtado-Alle
Journal:  Genet Mol Biol       Date:  2013-02-28       Impact factor: 1.771

Review 8.  Naturally Occurring Genetic Variants of Human Acetylcholinesterase and Butyrylcholinesterase and Their Potential Impact on the Risk of Toxicity from Cholinesterase Inhibitors.

Authors:  Oksana Lockridge; Robert B Norgren; Rudolph C Johnson; Thomas A Blake
Journal:  Chem Res Toxicol       Date:  2016-08-31       Impact factor: 3.739

9.  Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could BCHE Genotyping Be Helpful in Alzheimer's Therapy?

Authors:  Jacek Jasiecki; Bartosz Wasąg
Journal:  Biomolecules       Date:  2019-10-09

10.  Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.

Authors:  Herve Delacour; Sofya Lushchekina; Isabelle Mabboux; Aurore Bousquet; Franck Ceppa; Lawrence M Schopfer; Oksana Lockridge; Patrick Masson
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.